Compare Hilton Hotels Corporation Common Stock (HLT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Novavax Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $327.43 (market cap $72.76B), while Novavax Inc trades at $12.6 (market cap $1.82B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 40× Novavax Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Novavax Inc for 59 Days on average.
| HLT | NVAX | |
|---|---|---|
Market Cap | $72.76B | $1.82B |
Volume | 1,148,634 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $12.56 |
52-Week Low | $256.96 | $6.22 |
Typical Hold Time | 138 Days | 59 Days |
Enterprise Value | $85.78B | $1.39B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $320.5, down 0.65% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $348.11. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results expected soon. Revenue has grown steadily from $8.8B in 2022 to $12.04B in 2025, though net income margins have fluctuated. Recent news highlights institutional buying and positive travel trends for 2027.
The outlook for HLT is positive, supported by strong earnings performance, analyst optimism, and growth in travel demand. Key risks include high debt levels, with debt-to-asset ratio rising to 73.88% in 2025, and sensitivity to economic cycles affecting travel spending. The stock offers potential upside to the consensus target, but investors should monitor debt management and macroeconomic conditions.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
